Inventiva to present two abstracts on lanifibranor at EASL Congress 2026 in Barcelona

Inventiva, a clinical-stage biopharmaceutical company, announced it will present two research abstracts on its drug candidate lanifibranor at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. Lanifibranor is an oral small molecule designed to treat metabolic dysfunction-associated steatohepatitis (MASH) by activating all three PPAR isoforms, showing anti-fibrotic, anti-inflammatory, and metabolic benefits. The presentations will highlight lanifibranor's effects independent of weight change and its impact on liver cell structure. The drug has received Breakthrough Therapy and Fast Track designations from the FDA and is currently in a Phase 3 pivotal trial (NATiV3). Inventiva will also have a presence at the congress with a dedicated booth.